Caro RDC, et al. - In this investigation involving 20 patients with moderate-severe hidradenitis suppurativa (HS), researchers assessed the incidence of flares during 108 weeks of therapy and the clinical response to adalimumab. Individuals with moderate-severe HS treated with adalimumab were involved to assess the number of flares, average interval of time among flares, number of patients who reached the Hidradenitis Suppurativa Clinical Response (HiSCR), IHS4, pain VAS, lesions count and DLQI assessment. Data reported that 90% of patients reported at least 1 flare and a total of 48 flares were counted in all patients. The average time between flares was 26.9 ± 16.4 weeks. Despite the high number of flares, adalimumab is an effective and safe treatment for HS individuals.